



## Innate Immunity in HIV-1 Infection

Guest Editor:

**Dr. Mudit Tyagi**

Centre for Translational  
Medicine, Thomas Jefferson  
University, Philadelphia, PA  
19107, USA

Deadline for manuscript  
submissions:

**closed (31 March 2024)**

### Message from the Guest Editor

Dear colleagues,

This Special Issue delves into the complex interactions between the human immune system and the human immunodeficiency virus (HIV). Despite the efficacy of current anti-HIV drug regimens in controlling transmission and replication, HIV remains a significant global health challenge. The issue focuses on understanding the mechanisms of HIV pathogenesis, its life cycle, latency and available therapeutics. Efforts to eradicate or cure HIV have faced obstacles due to the persistence of latent HIV reservoirs. Additionally, preventive and therapeutic vaccines have encountered limited success due to the adaptability of the virus. Various prophylactic approaches, including microbicides, have struggled to produce desired outcomes. The research presented here aims to uncover insights into immune responses against HIV, identify vulnerabilities in viral replication and develop more effective vaccination strategies for combating the infection.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Ralph A. Tripp

Department of Infectious  
Diseases, College of Veterinary  
Medicine, University of Georgia,  
Athens, GA 30602-7387, USA

## Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

## Author Benefits

**Open Access:** free for readers, with **article processing charges (APC)** paid by authors or their institutions.

**High Visibility:** indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.**

**Journal Rank:** JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

## Contact Us

---

*Vaccines* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/vaccines](http://mdpi.com/journal/vaccines)  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)